Home Contact Sitemap

eRAM

encyclopedia of Rare Disease Annotation for Precision Medicine




Disease medullary thyroid carcinoma
Comorbidity C0027662|multiple endocrine neoplasia
Sentences 6
PubMedID- 22584721 We briefly review the surgical approaches to medullary thyroid carcinoma associated with multiple endocrine neoplasia type 2 (medullary thyroid carcinoma/multiple endocrine neoplasia type 2).
PubMedID- 22127824 Thyroid neoplasia preclinical rodent studies with liraglutide have shown an increase in c-cell thyroid cancer, which so far has not been demonstrated in monkeys or humans.25 based on the preclinical studies in rodents, the fda has requested a boxed warning for liraglutide, which includes contraindications for use in “...patients with a personal or family history of medullary thyroid carcinoma (mtc) or in patients with multiple endocrine neoplasia syndrome type 2 (men 2).”25 recent findings from a large screening study in 5000 subjects treated with liraglutide did not support an effect of glp-1 receptor activation on serum calcitonin levels in humans, as reported in rodent studies.26 however, ongoing studies are evaluating the long-term safety of incretinbased therapy.
PubMedID- 26487970 Acute coronary syndrome: a rare case of multiple endocrine neoplasia syndromes with pheochromocytoma and medullary thyroid carcinoma.
PubMedID- 23705087 Sonographic findings of medullary thyroid carcinoma leading to diagnosis of multiple endocrine neoplasia type 2a during pregnancy.
PubMedID- 23249377 There were five benign thyroid conditions and four thyroid cancers, including three papillary thyroid cancers and one bilateral medullary thyroid cancer in a patient with multiple endocrine neoplasia 2a.
PubMedID- 23979292 Surgical curability of medullary thyroid cancer in multiple endocrine neoplasia 2b: a changing perspective.

Page: 1